Mundipharma
Cathrin M. currently serves as Senior Manager in Global Finance Systems Insights & Development at Mundipharma, a position held since April 2016. Previous roles at Mundipharma include Senior Controlling Manager and Financial Controller, as well as Junior Controller for Austria and Central Eastern Europe. Prior to this, Cathrin M. worked as a Marketing Support Executive at bChannels from October 2014 to September 2015 and served as Executive Assistant to the General Manager at Zivilingenieurbüro Kuhn from February 2010 to September 2014. Academically, Cathrin M. holds a Bachelor of Science in Betriebswirtschaft from WU (Vienna University of Economics and Business) and has studied at the University of Oxford.
This person is not in any teams
This person is not in any offices
Mundipharma
5 followers
The Mundipharma global network of independent associated companies shares a common purpose to identify and accelerate the development of meaningful medicines that add value for patients and healthcare providers around the globe. Founded in the US by two physicians in 1952 and still privately owned, the network has a presence in over 120 countries. In Europe, the network employees more than 2,000 employees from R&D to manufacturing & supply and commercial, and with revenues in excess of €1 billion. At Mundipharma we strive for one high performing and learning environment where individuals can make a real difference. We have a strong track record of building successful alliances to license, develop and market medicines that improve patients’ lives, while also providing attractive options to financially constrained healthcare systems. Consistent with our entrepreneurial heritage, we like to think that we see what others don’t by challenging conventional wisdom and asking different and challenging questions. By working in partnership with all our stakeholders, the Mundipharma network develops medicines that create value for patients, payers and wider healthcare systems. We have built a European portfolio of medicines to create value for patients, payers and wider healthcare systems across important therapeutic areas such as diabetes, respiratory, oncology, pain and biosimilars.